Levothyroxine vs. Armour Thyroid: Which Is Right for You?

How Levothyroxine and Armour Thyroid Work Differently

Levothyroxine delivers synthetic thyroxine (T4 only). Your peripheral tissues, mainly the liver and kidneys, convert that T4 into the active hormone triiodothyronine (T3) through deiodinase enzymes. Armour Thyroid, made from porcine thyroid glands, contains both T4 and T3 in a fixed ratio of roughly 4.2:1 by mass [1].

That distinction matters because a subset of patients carry polymorphisms in the deiodinase type 2 gene (DIO2), which reduces peripheral T4-to-T3 conversion. A 2009 study published in the Annals of Internal Medicine (N=697) found that patients with the rs225014 DIO2 polymorphism reported meaningfully better psychological well-being and preference for T4/T3 combination therapy compared with T4 monotherapy [2]. Not every hypothyroid patient has this variant, but roughly 16% of the population does.

The fixed T4:T3 ratio in Armour is not identical to human thyroid output. A healthy human gland secretes T4 and T3 in a ratio closer to 14:1 to 20:1, so each grain of Armour delivers a disproportionately large T3 load [3]. That excess T3 can produce a brief but detectable spike in serum T3 within two to four hours of ingestion, something that does not occur with levothyroxine monotherapy. For patients with cardiac disease or arrhythmia risk, this peak may be clinically relevant.

Synthroid vs. Generic Levothyroxine: Are They Interchangeable?

The short answer is mostly yes, but with caveats. The FDA requires all levothyroxine formulations to contain between 95% and 105% of the labeled potency, and both branded Synthroid and generics from manufacturers like Mylan, Lannett, and IBSA (Tirosint) meet this specification [4]. A 2004 crossover pharmacokinetic study (N=30) found that three generic levothyroxine products were bioequivalent to Synthroid under fasting conditions [5].

Practical problems arise in two scenarios. First, switching between manufacturers mid-treatment can shift your actual delivered dose by up to 10% within that FDA window, enough to push TSH out of range in sensitive patients. Second, different inactive excipients, lactose in some tablets, acacia in others, affect absorption differently.

Tirosint addresses both issues. Its soft gelcap contains only levothyroxine, glycerin, gelatin, and water. A 2012 study (N=85) published in Thyroid showed that Tirosint produced significantly higher T4 absorption than standard levothyroxine tablets in patients with gastrointestinal conditions like atrophic gastritis (P<0.01) [6]. Patients with coffee-before-medication habits, proton-pump inhibitor use, or celiac disease may absorb Tirosint more consistently than tablet-based products.

The cost difference is real: generic levothyroxine runs roughly $10 to $20 per month at most pharmacies, Synthroid brand runs $40 to $80, and Tirosint lands around $60 to $100 without insurance. If your TSH is stable on a generic, there is no clinical reason to switch purely for brand preference.

What the Clinical Trials Actually Show

The 2019 randomized controlled trial by Idrees and colleagues (N=75) is the most-cited head-to-head comparison of DTE versus levothyroxine monotherapy [7]. After 16 weeks on each treatment in a crossover design, 48% of patients preferred DTE, 19% preferred levothyroxine, and 33% had no preference. Patients on DTE lost an average of 3 pounds more body weight over the study period, though TSH and free T4 did not differ significantly between groups.

The earlier Hoang et al. study (2013, N=70) in the Journal of Clinical Endocrinology and Metabolism found similar results: nearly half of participants preferred DTE, and those on DTE showed better scores on tests of general health, cognition, and mood [8].

Neither trial was large enough to assess cardiovascular outcomes, bone density effects, or long-term cancer risk. The American Thyroid Association (ATA) 2014 guidelines note: "There is currently insufficient evidence to support the routine use of combination T4+T3 therapy or desiccated thyroid extract in lieu of T4 monotherapy." [9] That guideline language does not say DTE is wrong for individual patients; it says the population-level evidence is not yet strong enough to change the default recommendation.

A practical clinical framework our medical team uses at HealthRX: levothyroxine monotherapy is the starting point for all newly diagnosed hypothyroid patients. A trial of DTE is considered after at least six months on optimized levothyroxine if the patient still reports residual fatigue, weight resistance, or cognitive difficulty and TSH sits in range. DIO2 genetic testing (available through standard labs) can inform that conversation but is not required before a DTE trial.

Dosing: How Much of Each Do You Need?

Levothyroxine full-replacement dosing runs approximately 1.6 mcg/kg/day for adults without residual thyroid function [10]. A 70 kg adult would typically start at 112 mcg/day. Older adults, patients with coronary artery disease, and those with severe longstanding hypothyroidism start lower, at 25 to 50 mcg/day, with upward titration every six to eight weeks guided by TSH. The goal TSH for most non-pregnant adults is 0.4 to 4.0 mIU/L, per the ATA [9].

Armour Thyroid dosing uses "grains": one grain equals 60 mg of desiccated thyroid and contains approximately 38 mcg T4 and 9 mcg T3. Because T3 is roughly three to four times more potent than T4 per microgram at the receptor level, one grain of Armour is considered roughly equivalent to 60 to 65 mcg of levothyroxine in T4-equivalence terms. Converting a patient from 100 mcg levothyroxine to Armour would put them in the range of 1.5 grains (90 mg) daily, though individual titration is always required.

TSH alone is less reliable as the sole monitoring parameter on DTE because the T3 component suppresses TSH more than an equivalent T4 dose would. Clinicians monitoring patients on Armour Thyroid should also check free T3 and free T4, not just TSH, at each adjustment visit.

Who Is a Better Candidate for Each Option?

Levothyroxine is likely the better fit if you:

• Have newly diagnosed primary hypothyroidism and have not yet tried any replacement therapy
• Have a history of atrial fibrillation or another arrhythmia (the T3 peak with DTE adds unnecessary risk)
• Are pregnant or planning pregnancy (the ATA specifically recommends levothyroxine during pregnancy [9])
• Have difficulty tolerating pork products for religious, ethical, or allergy-related reasons
• Need precise, consistent dosing, as in thyroid cancer suppression therapy where TSH must be kept below 0.1 mIU/L

Armour Thyroid may be worth discussing if you:

• Have documented normal or near-normal TSH on adequate levothyroxine but still have persistent hypothyroid symptoms
• Have tested positive for the DIO2 rs225014 polymorphism
• Prefer a naturally derived product and your physician is comfortable monitoring both free T3 and free T4
• Have tried multiple levothyroxine formulations, including Tirosint, without achieving symptom resolution

Neither option is universally superior. An experienced clinician who monitors both TSH and free thyroid hormone levels can make either work.

Treating Hyperthyroidism: Methimazole vs. PTU

The levothyroxine-versus-Armour debate covers hypothyroidism. A completely separate clinical decision arises for hyperthyroidism, where the question is often methimazole versus propylthiouracil (PTU) versus radioactive iodine versus surgery.

Methimazole is the first-line antithyroid drug for most adults with Graves disease, per ATA/AACE 2016 guidelines [11]. It blocks thyroid peroxidase, slowing new hormone synthesis. At standard doses of 10 to 30 mg/day, methimazole achieves euthyroidism in most patients within four to eight weeks. Its once-daily dosing (versus PTU's three-times-daily requirement) significantly improves adherence.

PTU is preferred in three situations: the first trimester of pregnancy (methimazole carries a small risk of embryopathy), thyroid storm (PTU also blocks peripheral T4-to-T3 conversion), and methimazole allergy or intolerance. PTU carries a rare but serious risk of fulminant hepatic failure, with an estimated incidence of 1 in 10,000 patients, which is why the FDA added a black-box warning in 2010 [12].

Agranulocytosis, a potentially life-threatening drop in white blood cells, occurs in roughly 0.1% to 0.5% of patients on either antithyroid drug. Patients should be instructed to stop the medication and seek immediate evaluation for any fever, sore throat, or mouth sores.

Radioactive Iodine vs. Thyroidectomy for Hyperthyroidism

When antithyroid drugs fail or are not appropriate for long-term use, patients face a choice between radioactive iodine (RAI, specifically iodine-131) and thyroidectomy.

RAI is non-surgical and effective. A single ablative dose renders 80% to 90% of Graves disease patients hypothyroid within six to twelve months, at which point they require levothyroxine for life [13]. RAI is contraindicated in pregnancy and is generally avoided in patients with moderate-to-severe active Graves ophthalmopathy, as it may worsen eye disease in 15% to 20% of cases [11].

Thyroidectomy, either total or near-total, achieves immediate, definitive cure of hyperthyroidism. In experienced hands, with surgeons performing more than 25 thyroidectomies per year, the rate of permanent hypoparathyroidism runs below 2% and permanent recurrent laryngeal nerve injury below 1% [14]. Patients with large goiters, suspected or confirmed thyroid malignancy, or significant ophthalmopathy are typically better served by surgery than RAI.

The ATA 2016 guidelines state: "The choice of therapy should be based on the clinical and biochemical severity of the disease, the presence of specific conditions such as Graves ophthalmopathy... and patient preference." [11] No single modality is right for all patients, which is why shared decision-making with an endocrinologist or thyroid surgeon is standard of care.

Practical Tips for Optimizing Thyroid Medication Absorption

Regardless of which thyroid medication you take, absorption can vary by as much as 40% based on timing and co-ingested substances. All levothyroxine-based products should be taken on an empty stomach, 30 to 60 minutes before breakfast or any coffee [15]. Calcium carbonate, iron supplements, cholestyramine, antacids containing aluminum or magnesium, and proton pump inhibitors all reduce levothyroxine absorption when taken within four hours of the dose.

For patients who truly cannot tolerate morning fasting, bedtime dosing of levothyroxine has been studied in a crossover trial (N=90, Bolk et al. 2010) and shown to produce modestly better TSH suppression and free T4 levels compared with morning dosing, likely because the GI tract is empty overnight [16].

Armour Thyroid tablets should similarly be taken on an empty stomach. Some clinicians split the daily DTE dose into a morning and midday dose to blunt the T3 peak, though this practice has not been tested in large randomized trials.

A TSH recheck four to eight weeks after any dose change, formulation change, or manufacturer switch is standard and allows timely dose correction before symptoms recur or worsen.

Monitoring Parameters and Lab Interpretation

TSH is the single most sensitive marker of thyroid hormone action at the pituitary level. A TSH above 4.0 mIU/L generally signals undertreatment; a TSH below 0.4 mIU/L signals overtreatment in most adults not being treated for thyroid cancer.

Free T4 should be checked at baseline and at any time TSH is unexpectedly abnormal. Free T3 is not routinely necessary for patients on levothyroxine monotherapy, but it becomes a meaningful monitoring tool when a patient is on DTE or when symptoms and TSH are discordant.

Anti-TPO antibody titers, positive in up to 90% of Hashimoto's thyroiditis cases, do not need to be rechecked after diagnosis [17]. They confirm autoimmune etiology but do not guide dose changes.

Patients on thyroid cancer suppression therapy, typically maintained at a TSH below 0.1 mIU/L, should have annual bone mineral density checks if suppression continues beyond two to three years, as subclinical hyperthyroidism accelerates bone resorption and raises fracture risk [9].

A woman with hypothyroidism who becomes pregnant should increase her levothyroxine dose by approximately 25 to 30% immediately upon a positive pregnancy test and notify her provider for recheck within four weeks. Uncontrolled hypothyroidism in the first trimester is associated with lower IQ scores in offspring and increased miscarriage risk [18].